RHOC and neoplasm: On another hand, the presence of RhoC-specific T cells before vaccination or in the placebo control group (Figure 3) strongly suggests that in vivo T cell priming was taking place in some patients; hence, that RhoC is a tumor antigen that can spontaneously give rise to T cell responses.